Literature DB >> 17224217

Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients.

Xin Yao1, Bojian Zheng, Jie Zhou, Dao-Zhen Xu, Kai Zhao, Shu-Hui Sun, Zheng-Hong Yuan, Yu-Mei Wen.   

Abstract

To study the responses of chronic hepatitis B patients to yeast-derived HBsAg-HBIG complexes (YIC) and the mechanisms involved, twenty HBeAg-positive chronic hepatitis B patients were immunized with 60microg of YIC or alum as the control at 4-week intervals, for 24 weeks. Five of ten patients responded to 60microg YIC immunization showing > or =2 logs decrease of serum HBV DNA with loss or marked reduction of HBeAg and appearance of anti-HBe; two of these patients developed anti-HBs. Flares of alanine aminotransferase were observed in 4 of the 5 responders, and in 2 out of 10 control patients. HBsAg-stimulated peripheral blood mononuclear cells (PBMCs) secreted Th1/Th2 cytokines around 24 weeks after immunization. Dendritic cells incubated with YIC showed the highest levels of IL-12 secretion and up-regulation of functional markers. Thus, the therapeutic effect of YIC is associated with cytolytic and non-cytolytic responses in patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17224217     DOI: 10.1016/j.vaccine.2006.11.019

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

1.  Immuno-potentiating pathway of HBsAg-HBIG immunogenic complex visualized.

Authors:  Hu Liu; Shuang Geng; Bo Wang; Bing Wu; Xiaoping Xie; Shuang Wang; Yiwei Zhong; Xuanyi Wang; Di Qu; Yumei Wen; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

2.  Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.

Authors:  Yuan Hong; Yibing Peng; Michael Mi; Haiyan Xiao; David H Munn; Gui-Qiang Wang; Yukai He
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

Review 3.  New therapeutic vaccination strategies for the treatment of chronic hepatitis B.

Authors:  Jia Liu; Anna Kosinska; Mengji Lu; Michael Roggendorf
Journal:  Virol Sin       Date:  2014-01-17       Impact factor: 4.327

Review 4.  Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?

Authors:  Sarene Koh; Antonio Bertoletti
Journal:  Med Microbiol Immunol       Date:  2014-12-16       Impact factor: 3.402

5.  Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.

Authors:  Chenliang Zhou; Chaofan Li; Guo-Zhong Gong; Shuang Wang; Ji-Ming Zhang; Dao-Zhen Xu; Li-Min Guo; Hong Ren; Min Xu; Qing Xie; Chen Pan; Jie Xu; Zhongyu Hu; Shuang Geng; Xian Zhou; Xianzheng Wang; Xiaoyu Zhou; Haili Mi; Gan Zhao; Wencong Yu; Yu-Mei Wen; Lihua Huang; Xuan-Yi Wang; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2017-06-30       Impact factor: 3.452

6.  HBV life cycle and novel drug targets.

Authors:  Daniel Grimm; Robert Thimme; Hubert E Blum
Journal:  Hepatol Int       Date:  2011-03-08       Impact factor: 6.047

Review 7.  Treatment of hepatitis B virus: an update.

Authors:  Haley Ward; Lydia Tang; Bhawna Poonia; Shyam Kottilil
Journal:  Future Microbiol       Date:  2016-11-18       Impact factor: 3.165

8.  Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection.

Authors:  Xiaochen Tian; Chao Zhao; Hongguang Zhu; Weimin She; Jiming Zhang; Jing Liu; Lanjuan Li; Shusen Zheng; Yu-Mei Wen; Youhua Xie
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy.

Authors:  Henri-Alexandre Michaud; Tiphanie Gomard; Laurent Gros; Kevin Thiolon; Roudaina Nasser; Chantal Jacquet; Javier Hernandez; Marc Piechaczyk; Mireia Pelegrin
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

10.  Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model.

Authors:  Mengji Lu; Xin Yao; Yang Xu; Heike Lorenz; Uta Dahmen; Haidong Chi; Olaf Dirsch; Thekla Kemper; Lifang He; Dieter Glebe; Wolfram H Gerlich; Yumei Wen; Michael Roggendorf
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.